Amgen, Plexium Collaborate To Identify Novel Targeted Protein Degradation Therapies

Amgen (AMGN) and Plexium Inc. have entered into multi-year, drug discovery collaboration to identify novel targeted protein degradation therapies.

The collaboration combines Plexium's novel technology platform with Amgen's early discovery expertise to identify and develop new therapeutic agents in cancer and other serious diseases, Amgen said in a statement.